公开(公告)号：EP2132226A4

公开(公告)日：2012-12-26

申请号：EP08730569

申请日：2008-02-22

申请人： BAYLOR RES INST

发明人： BANCHEREAU JACQUES F ,  OH SANGKON ,  ZURAWSKI GERARD ,  ZURAWSKI SANDRA ,  LI DAPENG

IPC分类号： C07K16/28 ,  A61K39/00 ,  A61P37/00

CPC分类号： A61K47/48369 ,  A61K2039/5154 ,  A61K2039/55516 ,  C07K16/28 ,  C07K2317/92 ,  C07K2319/01 ,  C07K2319/33

摘要： The present invention includes compositions and methods for targeting the LOX-1 receptor on immune cells and uses for the anti-LOX-1 antibodies.

摘要翻译： 本发明包括用于靶向免疫细胞上的LOX-1受体的组合物和方法以及抗LOX-1抗体的用途。

公开(公告)号：EP1910408B1

公开(公告)日：2010-02-17

申请号：EP06783852.4

申请日：2006-07-20

申请人： Applied NanoSystems B.V.

发明人： LEENHOUTS, Cornelis, Johannes ,  VAN ROSMALEN, Maarten, Leonardus ,  BOSMA, Tjibbe

IPC分类号： C07K14/335 ,  A61K39/39 ,  A61K39/385 ,  A61P31/00 ,  A61P33/00 ,  A61P35/00 ,  A61P37/00

CPC分类号： A61K47/48369 ,  A61K39/385 ,  A61K47/68 ,  A61K2039/541 ,  A61K2039/55555 ,  A61K2039/6056 ,  A61K2039/6068 ,  A61K2039/622 ,  C07K14/335 ,  C07K16/18 ,  C07K2319/70 ,  C07K2319/705

公开(公告)号：EP1682581A4

公开(公告)日：2008-11-05

申请号：EP04800089

申请日：2004-11-13

申请人： HANMI PHARMACEUTICAL CO LTD

发明人： JUNG SUNG YOUB ,  KIM JIN SUN ,  YANG GEUN HEE ,  KWON SE CHANG ,  LEE GWAN SUN

IPC分类号： A61K47/42 ,  C07K19/00 ,  A61K47/48 ,  C07K16/00 ,  C07K16/42 ,  C12N15/70

CPC分类号： A61K47/68 ,  A61K47/48369 ,  A61K47/6811 ,  A61K47/6813 ,  A61K47/6835 ,  C07K14/505 ,  C07K14/535 ,  C07K14/56 ,  C07K14/61 ,  C07K16/46 ,  C07K19/00 ,  C07K2317/52 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2319/30

摘要： Disclosed is a novel use of an immunoglobulin Fc fragment, and more particularly, a pharmaceutical composition comprising an immunoglobulin Fc fragment as a carrier. The pharmaceutical composition comprising an immunoglobulin Fc fragment as a carrier remarkably extends the serum half-life of a drug while maintaining the in vivo activity of the drug at relatively high levels. Also, when the drug is a polypeptide drug, the pharmaceutical composition has less risk of inducing immune responses compared to a fusion protein of the immunoglobulin Fc fragment and a target protein, and is thus useful for developing long-acting formulations of various polypeptide drugs.

公开(公告)号：EP1746103A1

公开(公告)日：2007-01-24

申请号：EP05076680.7

申请日：2005-07-20

申请人： Applied NanoSystems B.V.

发明人： The designation of the inventor has not yet been filed

IPC分类号： C07K14/335 ,  A61K39/39 ,  A61K39/385 ,  A61P31/00 ,  A61P33/00 ,  A61P35/00 ,  A61P37/00

CPC分类号： A61K47/48369 ,  A61K39/385 ,  A61K47/68 ,  A61K2039/541 ,  A61K2039/55555 ,  A61K2039/6056 ,  A61K2039/6068 ,  A61K2039/622 ,  C07K14/335 ,  C07K16/18 ,  C07K2319/70 ,  C07K2319/705

摘要： The invention relates to the areas of immunology and vaccine delivery. More specifically, it relates to a bacterial vaccine delivery technology with built-in immunostimulatory properties which allows the immobilization of any antigen of interest, without prior antigen modification. Provided is an antigen binding immunogenic carrier complex comprising at least one bifunctional polypeptide attached to an immunogenic carrier, said bifunctional polypeptide comprising a peptidoglycan binding domain (PBD) through which the polypeptide is attached to said carrier, fused to an antigen binding domain (ABD) capable of binding an antigen of interest. Also provided is a pharmaceutical (e.g. vaccine) composition comprising an antigen-loaded immunogenic carrier complex of the invention.

摘要翻译： 本发明涉及免疫学和疫苗递送领域。 更具体地说，本发明涉及具有内在免疫刺激性质的细菌疫苗递送技术，其允许固定目标抗原，而无需先前的抗原修饰。 本发明提供了一种抗原结合免疫原性载体复合物，其包含至少一个与免疫原性载体连接的双功能多肽，所述双功能多肽包含肽聚糖结合结构域（PBD），多肽与所述载体连接，融合至抗原结合结构域（ABD） 能够结合感兴趣的抗原。 还提供了包含本发明的抗原负载的免疫原性载体复合物的药物（例如疫苗）组合物。

公开(公告)号：EP3233920A4

公开(公告)日：2018-07-25

申请号：EP15871152

申请日：2015-12-18

申请人： ALKERMES INC

发明人： ALVARAZ JUAN ,  MOUSTAKAS DEMETRI T ,  BRODKIN HEATHER R ,  MCSWEENEY LESLIE A

IPC分类号： C07K16/30

CPC分类号： A61K47/48369 ,  A61K38/00 ,  A61K38/179 ,  A61K38/1793 ,  A61K38/2013 ,  A61K38/2066 ,  A61K38/215 ,  A61K38/4846 ,  C07K14/5428 ,  C07K14/55 ,  C07K14/565 ,  C07K14/70578 ,  C07K14/7151 ,  C07K14/7155 ,  C07K2319/30 ,  C07K2319/70 ,  C12N9/644 ,  C12Y304/21022

摘要： The present invention provides novel, single chain Fc fusion proteins having improved properties. The invention provides single chain fusions of soluble proteins fused to the Fc region of an immunoglobulin via a novel linker comprising a constant region of an immunoglobulin light chain linked to a CH1 constant region of an immunoglobulin heavy chain. This novel linker confers favorable properties on the Fc fusion proteins of the invention such as improved bioactivity and increased half-life as compared to non-Fc fusion counterparts or as compared to prior art Fc fusion proteins. The novel Fc fusion protein scaffold as described herein may be designed to include soluble proteins of interest capable of binding or interacting with any target of interest. Preferably, the Fc fusion protein of the invention is a dimer. The dimer preferably forms via a disulfide bond between free cysteine residues in the hinge region of two monomeric Fc fusion proteins of the invention.

公开(公告)号：EP3129357A4

公开(公告)日：2018-06-13

申请号：EP15776253

申请日：2015-04-09

申请人： AF CHEMICALS LLC

发明人： KELNER MICHAEL

IPC分类号： C07D235/02 ,  A01N47/10 ,  C07C209/62 ,  C07D493/00

CPC分类号： A61K31/122 ,  A61K31/19 ,  A61K47/481 ,  A61K47/48107 ,  A61K47/48123 ,  A61K47/48238 ,  A61K47/48246 ,  A61K47/48261 ,  A61K47/48269 ,  A61K47/48338 ,  A61K47/48369 ,  A61K47/48384 ,  A61K47/48715 ,  A61K47/551 ,  A61K47/554 ,  A61K47/62 ,  A61K47/642 ,  A61K47/6803 ,  A61K47/6889

摘要： In an embodiment of the invention, a composition for treating a cell population comprises an Affinity Medicant Conjugate (AMC). The medicant moiety can be a toxin including an acylfulvene or a drug moiety. The affinity moiety can be an antibody, a binding protein, a steroid, a lipid, a growth factor, a protein, a peptide or non peptidic. The affinity moiety can be covalently bound to the medicant via a linker. Novel linkers that can be directed to cysteine, arginine or lysine residues based on solution pH allow greater flexibility in preserving and/or generating specific epitopes in the AMC.

公开(公告)号：EP3142700A4

公开(公告)日：2018-05-02

申请号：EP15793257

申请日：2015-05-15

申请人： MEDIMMUNE LLC

发明人： TSUI PING ,  BORROK MARTIN ,  DALL'ACQUA WILLIAM ,  WU YANLI ,  BEYAZ-KAVUNCU NURTEN

IPC分类号： A61K39/395 ,  C07K16/00

CPC分类号： C07K16/40 ,  A61K47/48369 ,  A61K47/68 ,  A61K2039/505 ,  C07K16/00 ,  C07K16/005 ,  C07K16/1027 ,  C07K16/2887 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/524 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/00 ,  C07K2319/30

摘要： The present invention provides molecules, including proteins, more particularly, immunoglobulins whose in vivo half-lives are altered (increased or decreased) by the presence of an IgG, constant domain, or FcRn binding fragment thereof (e.g., an Fc region or hinge-Fc region) (e.g., from a human IgGI, e.g., human IgGI), that have modifications of one or more of amino acid residues in at least the CH3 domain.

公开(公告)号：EP3129357A2

公开(公告)日：2017-02-15

申请号：EP15776253.5

申请日：2015-04-09

申请人： AF Chemicals LLC

发明人： KELNER, Michael

IPC分类号： C07D235/02 ,  C07C209/62 ,  C07D493/00 ,  A01N47/10

CPC分类号： A61K31/122 ,  A61K31/19 ,  A61K47/481 ,  A61K47/48246 ,  A61K47/48261 ,  A61K47/48338 ,  A61K47/48369 ,  A61K47/551 ,  A61K47/554 ,  A61K47/62 ,  A61K47/642 ,  A61K47/6803 ,  A61K47/6889

摘要： In an embodiment of the invention, a composition for treating a cell population comprises an Affinity Medicant Conjugate (AMC). The medicant moiety can be a toxin including an acylfulvene or a drug moiety. The affinity moiety can be an antibody, a binding protein, a steroid, a lipid, a growth factor, a protein, a peptide or non peptidic. The affinity moiety can be covalently bound to the medicant via a linker. Novel linkers that can be directed to cysteine, arginine or lysine residues based on solution pH allow greater flexibility in preserving and/or generating specific epitopes in the AMC.

摘要翻译： 在本发明的一个实施方案中，用于治疗细胞群的组合物包含亲和药物偶联物（AMC）。 药物部分可以是包括酰基富含物或药物部分的毒素。 亲和部分可以是抗体，结合蛋白，类固醇，脂质，生长因子，蛋白质，肽或非肽。 亲和部分可以通过接头与药物共价结合。 可以基于溶液pH针对半胱氨酸，精氨酸或赖氨酸残基的新型接头允许在AMC中保留和/或生成特定表位的更大灵活性。

公开(公告)号：EP2525823A4

公开(公告)日：2016-01-27

申请号：EP11735263

申请日：2011-01-21

申请人： HOFFMANN LA ROCHE

发明人： WATTS RYAN J ,  YU JOY ,  DENNIS MARK ,  FRESKGARD PER-OLA ,  TAM STEPHEN

IPC分类号： A61K39/395 ,  A61K38/17 ,  A61K48/00 ,  A61P25/00 ,  A61P25/16 ,  A61P25/28

CPC分类号： A61K47/48369 ,  A61K38/00 ,  A61K39/3955 ,  A61K47/6849 ,  C07K16/28

公开(公告)号：EP2968582A1

公开(公告)日：2016-01-20

申请号：EP14710276.8

申请日：2014-03-14

申请人： Innate Pharma

发明人： BREGEON, Delphine

IPC分类号： A61K47/48

CPC分类号： A61K47/48369 ,  A61K47/68 ,  A61K47/6803 ,  C07K16/00 ,  C07K2317/41

摘要： Some embodiments described herein relate to solid-support based processess for the functionalization of immunoglobulins through the use of transglutaminase. Also provided are solid support compositions with bound antibody. The methods can be used, for example, in manufacturing processes or in drug screening.